InvnTree

Cancer Is Not One Disease | Ideas to Assets

Cancer is often spoken about as if it’s a single problem.
But in reality, it’s an entire universe of diseases.

In this clip from Ideas to Assets: The IP Talk, Shamim explains why it’s not feasible to have one drug that treats all cancers. Even within something as specific as liver cancer, there are multiple sub-types each behaving differently and requiring different treatment approaches.

That’s why modern cancer research focuses on specific cancers, specific pathways, and specific patient groups, rather than searching for one universal solution.

It’s a reminder of how complex this field truly is and why progress happens step by step, not all at once.

🌐 www.invntree.com

Drug discovery isn’t about one expert.

Drug discovery, whether in oncology or any other therapeutic area, is deeply complex.
No single person can do it alone.

In this clip from Ideas to Assets: The IP Talk, Shamim explains how progress happens only when multiple disciplines come together, biochemistry, cell and molecular biology, genetics, chemistry, molecular modeling, IP, and more.

Everyone plays a role.
Not everyone understands everything.
But together, the team sees the potential and solves the right problems.

That’s what makes this field special.
It keeps evolving.
Every project is different.
And even after years, there’s always something new to learn.

A powerful reminder that innovation is built by teams, culture, and curiosity.

🎥 Full episode on YouTube
🌐 www.invntree.com

💪

Android vs iPhone ⚡
More Features ≠ Better Value

More isn’t always better - in tech or in IP.

In this clip from Ideas to Assets: The IP Talk, Hemanth Puttaiah (Co-Founder, InvnTree) and Arvin T (Head of IP Strategy, Simple Energy) compare Android and iPhone to explain how quality patents often outperform bulk filings.

It’s not about how many patents you have - it’s about how strategic and relevant they are to your business.

🎥 Full podcast on YouTube
🌐 www.invntree.com